Tumor Markers and Their Prognostic Value in Sinonasal ITAC/Non-ITAC

Survivorship in Tumors of the Sinonasal Tract: The Need for Improved Awareness, Patient Education, and an Emphasis on Multi-Disciplinary Care

Sinonasal cancer treatment confers extensive and diverse sequela, which may persist for months to years after treatment or manifest as late effects. Furthermore, recurrences are common for some subtypes and may occur beyond five years post-treatment of the initial malignancy. Altogether, these can place a substantial physical, psychosocial, and economic burden on the survivor. Due to the rarity of these cancers, there are limited data to comprehensively elucidate the landscape of treatment-related morbidity in the long term. Furthermore, survivors may lack awareness of the entirety of possible adverse effects, which may exacerbate their long-term psychosocial well-being and quality of life, and delay attainment of appropriate care. To enable the development of patient education strategies and provide clinicians with up-to-date, evidence-based information on the long-term and/or late morbidity associated with sinonasal cancer treatment, a comprehensive review was performed. There is a wide range of issues that survivors face, both due to the sinonasal cancer itself and as a result of the treatment, highlighting the need for multidisciplinary survivorship care. Importantly, survivorship care will greatly benefit from patient and public involvement, alongside input from medical, surgical, and allied health professionals, to ensure that all aspects of care are addressed throughout the survivor journey.

Biomarkers of Tumor Metastasis and Invasiveness

The identification of proteins as new cancer diagnostic and prognostic biomarkers continues to attract considerable attention in the oncology literature, especially in the context of invasion and metastasis activation process [...].